Pictet Asset Management Holding SA Purchases Shares of 354,012 Tyra Biosciences, Inc. (NASDAQ:TYRA)

Pictet Asset Management Holding SA purchased a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 354,012 shares of the company's stock, valued at approximately $4,921,000. Pictet Asset Management Holding SA owned approximately 0.70% of Tyra Biosciences at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Alta Partners Management Company L.P. bought a new position in Tyra Biosciences during the 4th quarter valued at about $56,716,000. FMR LLC lifted its position in Tyra Biosciences by 0.8% during the third quarter. FMR LLC now owns 3,372,850 shares of the company's stock valued at $79,296,000 after purchasing an additional 26,187 shares during the period. Janus Henderson Group PLC purchased a new stake in Tyra Biosciences in the third quarter worth approximately $24,994,000. State Street Corp grew its position in Tyra Biosciences by 4.4% in the 3rd quarter. State Street Corp now owns 384,732 shares of the company's stock worth $9,045,000 after purchasing an additional 16,248 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Tyra Biosciences by 1.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company's stock valued at $8,667,000 after buying an additional 3,896 shares during the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 3,993 shares of Tyra Biosciences stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total transaction of $65,325.48. Following the sale, the director now owns 3,707,420 shares of the company's stock, valued at approximately $60,653,391.20. This trade represents a 0.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders have sold 21,998 shares of company stock worth $344,818. 15.40% of the stock is owned by corporate insiders.

Remove Ads

Tyra Biosciences Stock Performance

Shares of NASDAQ TYRA traded down $0.32 during trading on Tuesday, hitting $7.06. The company had a trading volume of 287,861 shares, compared to its average volume of 240,548. The stock has a 50 day simple moving average of $11.24 and a 200 day simple moving average of $15.55. The firm has a market capitalization of $374.82 million, a P/E ratio of -4.39 and a beta of 1.19. Tyra Biosciences, Inc. has a 12 month low of $6.97 and a 12 month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.05. As a group, analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TYRA. HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, March 31st. Wedbush restated an "outperform" rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, March 28th. Finally, UBS Group began coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences presently has an average rating of "Buy" and an average price target of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.